Biotech & Life Sciences

While everyone chases AI drug discovery, Blackstone just raised $6.3B to profit from the unglamorous, expensive work of actually running clinical trials.

Guidelines called for restricting it to high-risk patients. A massive new trial suggests that was exactly backwards.

Eli Lilly is funding the AI company trying to disrupt its own $20B obesity franchise. That's not a bug — it's the deal.

Imagine keeping 2,600 outfits organized in one closet, instantly grabbing the one you need while the rest vanish. That's what your immune system is up against.

Renaud raised $1 billion without a single approved drug — a war chest that dwarfs most biotech IPOs.

On a Sunday morning, Eli Lilly quietly placed a bet that its own future could obsolete its present.

When the [CLOSURE-AF trial](https://pubmed.ncbi.nlm.nih.gov/41849741/) landed in the New England Journal of Medicine, Eric Topol noticed something striking: the journal published an accompanying editorial — and a cardiologist reached the opposite conclusion via a separate interview.

Brown fat has been studied as an energy-burning cell for decades.

You get sick.

The biggest problem with putting living cells inside your body to make drugs is that the cells need oxygen — and subcutaneous tissue, where you'd implant them, doesn't have much to spare.

Otsuka Pharmaceutical is acquiring Transcend Therapeutics, a New York-based clinical-stage biotech, for $700 million upfront with up to $525 million in milestone payments — [a deal valued at $1.225 billion](https://www.prnewswire.com/news-releases/otsuka-pharmaceutical-to-acquire-transcend-therap...